Katena Products Announces the Acquisition of ASICO, LLC

Katena Products, Inc. is a provider of premium ophthalmic instruments, biologics, and devices to hospitals, surgical centers, and ophthalmic and optometric offices.

April 14, 2021

Katena Products, Inc. is a provider of premium ophthalmic instruments, biologics, and devices to hospitals, surgical centers, and ophthalmic and optometric offices.

ASICO has been an industry leader for over 35 years – providing high-quality ophthalmic surgical instruments, with special focus on the design of new products and technologies. ASICO’s product range encompasses over 1,500 items including stainless steel and titanium instruments, single-use cannulas and blades, and selection of diamond knives.

“Acquiring the ASICO business complements our ophthalmic surgical portfolio and provides Katena increased reach globally, capitalizing on ASICO’s network of renowned clinical key-opinion-leaders. Once integrated, we expect to provide our customers with an even more-comprehensive value proposition,” says Steve Blazejewski, CEO of Katena.

“We are happy to bring our track record of high-quality, high-performance surgical instruments to Katena, where ASICO’s portfolio will fit naturally,” says Ravi Nallakrishnan, former President of ASICO, LLC.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

April 30, 2025

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

April 24, 2025

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.